Skip to main content
Top
Published in: Breast Cancer Research and Treatment 3/2011

01-10-2011 | Preclinical study

Acquisition of metastatic tissue from patients with bone metastases from breast cancer

Authors: J. F. Hilton, E. Amir, S. Hopkins, M. Nabavi, G. DiPrimio, A. Sheikh, S. J. Done, D. Gianfelice, F. Kanji, S. Dent, D. Barth, N. Bouganim, A. Al-Najjar, M. Clemons

Published in: Breast Cancer Research and Treatment | Issue 3/2011

Login to get access

Abstract

Biopsies of metastatic tissue are increasingly being performed. Bone is the most frequent site of metastasis in breast cancer patients, but bone remains technically challenging to biopsy. Difficulties with both tissue acquisition and techniques for analysis of hormone receptor status are well described. Bone biopsies can be carried out by either by standard posterior iliac crest bone marrow trephine/aspiration or CT-guided biopsy of a radiologically evident bone metastasis. The differential yield of these techniques is unknown. Results from three prospective studies of similar methodology were pooled. Patients underwent both an outpatient posterior iliac crest bone marrow trephine/aspiration and a CT-guided biopsy of a radiologically evident bone metastasis. Samples were assessed for the presence of malignant cells and where possible also for estrogen (ER) and progesterone receptor (PgR) expression. 40 patients were enrolled. Bone marrow aspiration/trephine biopsy was completed in 39/40 (97.5%) and CT-guided biopsy was completed in 34/40 (85%) of patients. Sufficient tumor cells for hormone receptor analysis were available in 19/39 (48.8%) and 16/34 (47%) of and bone marrow aspiration/trephine and CT-guided biopsies, respectively. Significant discordance in ER and PgR between the primary and the bone metastasis was also seen. Nine patients had tissue available from both bone marrow and CT-guided bone biopsies. ER and PgR concordance between these sites was 100 and 78%, respectively. Performing studies on human bone metastases is technically challenging, with relatively low yields regardless of technique. Given resource issues and similar success rates when comparing both techniques, bone marrow examination may be utilized first and if inadequate tissue is obtained, CT-guided biopsies can then be used.
Literature
1.
go back to reference Amir E, Clemons M (2009) Should a biopsy be recommended to confirm metastatic disease in women with breast cancer? Lancet Oncol 10:933–935PubMedCrossRef Amir E, Clemons M (2009) Should a biopsy be recommended to confirm metastatic disease in women with breast cancer? Lancet Oncol 10:933–935PubMedCrossRef
2.
go back to reference Amir E, Clemons M, Freedman OC, Miller NR, Coleman RE, Purdie C, Jordan L, Quinlan P, Thompson AM (2010)Tissue confirmation of disease recurrence in patients with breast cancer: pooled analysis of two large prospective studies. J Clin Oncol 228:s1007 Amir E, Clemons M, Freedman OC, Miller NR, Coleman RE, Purdie C, Jordan L, Quinlan P, Thompson AM (2010)Tissue confirmation of disease recurrence in patients with breast cancer: pooled analysis of two large prospective studies. J Clin Oncol 228:s1007
3.
go back to reference Locatelli MA, Curigliano G, Fumagalli L, Bagnardi V, Aurilio G, Della Vigna P, Monfardini L, Giudici S, Viale G, Goldhirsch A (2010) Should liver metastases of breast cancer be biopsied to improve treatment choice? J Clin Oncol 28:s1008 Locatelli MA, Curigliano G, Fumagalli L, Bagnardi V, Aurilio G, Della Vigna P, Monfardini L, Giudici S, Viale G, Goldhirsch A (2010) Should liver metastases of breast cancer be biopsied to improve treatment choice? J Clin Oncol 28:s1008
4.
go back to reference Karlsson E, Lindström LS, Wilking U, Skoog L, Johansson U, Bergh J (2010) Discordance in hormone receptor status in breast cancer during tumor progression. J Clin Oncol 28:s1009 Karlsson E, Lindström LS, Wilking U, Skoog L, Johansson U, Bergh J (2010) Discordance in hormone receptor status in breast cancer during tumor progression. J Clin Oncol 28:s1009
5.
go back to reference Simmons C, Miller N, Geddie W, Gianfelice D, Oldfield M, Dranitsaris G, Clemons MJ (2009) Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol 20:1499–1504PubMedCrossRef Simmons C, Miller N, Geddie W, Gianfelice D, Oldfield M, Dranitsaris G, Clemons MJ (2009) Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol 20:1499–1504PubMedCrossRef
6.
go back to reference Broom RJ, Tang PA, Simmons C, Bordeleau L, Mulligan AM, O’Malley FP, Miller N, Andrulis IL, Brenner DM, Clemons MJ (2009) Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer. Anticancer Res 29:1557–1562PubMed Broom RJ, Tang PA, Simmons C, Bordeleau L, Mulligan AM, O’Malley FP, Miller N, Andrulis IL, Brenner DM, Clemons MJ (2009) Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer. Anticancer Res 29:1557–1562PubMed
7.
go back to reference Lower EE, Glass EL, Bradley DA, Blau R, Heffelfinger S (2005) Impact of metastatic ER and PR status on survival. Breast Cancer Res Treat 90:65–70PubMedCrossRef Lower EE, Glass EL, Bradley DA, Blau R, Heffelfinger S (2005) Impact of metastatic ER and PR status on survival. Breast Cancer Res Treat 90:65–70PubMedCrossRef
8.
go back to reference Lipton A, Leitzel K, Ali SM, Demers L, Harvey HA, Chaudri-Ross HA, Evans D, Lang R, Hackl W, Hamer P, Carney W (2005) Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. Cancer 104:257–263PubMedCrossRef Lipton A, Leitzel K, Ali SM, Demers L, Harvey HA, Chaudri-Ross HA, Evans D, Lang R, Hackl W, Hamer P, Carney W (2005) Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. Cancer 104:257–263PubMedCrossRef
9.
go back to reference Regitnig P, Schippinger W, Lindbauer M, Samonigg H, Lax SF (2004) Change of HER-2/neu status in a subset of distant metastases from breast carcinomas. J Pathol 203:918–926PubMedCrossRef Regitnig P, Schippinger W, Lindbauer M, Samonigg H, Lax SF (2004) Change of HER-2/neu status in a subset of distant metastases from breast carcinomas. J Pathol 203:918–926PubMedCrossRef
10.
go back to reference Li BD, Byskosh A, Molteni A, Duda RB (1994) Estrogen and progesterone receptor concordance between primary and recurrent breast cancer. J Surg Oncol 57:71–77PubMedCrossRef Li BD, Byskosh A, Molteni A, Duda RB (1994) Estrogen and progesterone receptor concordance between primary and recurrent breast cancer. J Surg Oncol 57:71–77PubMedCrossRef
11.
go back to reference Mobbs BG, Fish EB, Pritchard KI, Oldfield G, Hanna WH (1987) Estrogen and progesterone receptor content of primary and secondary breast cancer: influence of time and treatment. Eur J Cancer Clin Oncol 23:819–826PubMedCrossRef Mobbs BG, Fish EB, Pritchard KI, Oldfield G, Hanna WH (1987) Estrogen and progesterone receptor content of primary and secondary breast cancer: influence of time and treatment. Eur J Cancer Clin Oncol 23:819–826PubMedCrossRef
12.
go back to reference Raemaekers JM, Beex LV, Koenders AJ, Pieters GF, Smals AG, Benraad TJ, Kloppenborg PW (1984) Concordance and discordance of estrogen and progesterone receptor content in sequential biopsies of patients with advanced breast cancer: relation to survival. Eur J Cancer Clin Oncol 20:1011–1018PubMedCrossRef Raemaekers JM, Beex LV, Koenders AJ, Pieters GF, Smals AG, Benraad TJ, Kloppenborg PW (1984) Concordance and discordance of estrogen and progesterone receptor content in sequential biopsies of patients with advanced breast cancer: relation to survival. Eur J Cancer Clin Oncol 20:1011–1018PubMedCrossRef
13.
go back to reference Holdaway IM, Bowditch JV (1983) Variation in receptor status between primary and metastatic breast cancer. Cancer 52:479–485PubMedCrossRef Holdaway IM, Bowditch JV (1983) Variation in receptor status between primary and metastatic breast cancer. Cancer 52:479–485PubMedCrossRef
14.
go back to reference Hull DF, Clark GM, Osborne CK, Chamness GC, Knight WA III, McGuire WL (1983) Multiple estrogen receptor assays in human breast cancer. Cancer Res 43:413–416PubMed Hull DF, Clark GM, Osborne CK, Chamness GC, Knight WA III, McGuire WL (1983) Multiple estrogen receptor assays in human breast cancer. Cancer Res 43:413–416PubMed
16.
go back to reference Cawthorn TR, Amir E, Broom R, Freedman O, Gianfelice D, Barth D, Wang D, Holen I, Done SJ, Clemons M (2009) Mechanisms and pathways of bone metastasis: challenges and pitfalls of performing molecular research on patient samples. Clin Exp Metastasis 26:935–943PubMedCrossRef Cawthorn TR, Amir E, Broom R, Freedman O, Gianfelice D, Barth D, Wang D, Holen I, Done SJ, Clemons M (2009) Mechanisms and pathways of bone metastasis: challenges and pitfalls of performing molecular research on patient samples. Clin Exp Metastasis 26:935–943PubMedCrossRef
17.
go back to reference Amir E, Miller N, Geddie W et al (2010) Can bone biopsies be used to confirm metastatic disease recurrence and receptor status in breast cancer patients? In: 10th International Conference. Cancer-induced bone disease, 22–25 September, Sheffield, UK, Abstract P16 Amir E, Miller N, Geddie W et al (2010) Can bone biopsies be used to confirm metastatic disease recurrence and receptor status in breast cancer patients? In: 10th International Conference. Cancer-induced bone disease, 22–25 September, Sheffield, UK, Abstract P16
18.
go back to reference Diaz LK, Sneige N (2005) Estrogen receptor analysis for breast cancer: current issues and keys to increasing testing accuracy. Adv Anat Pathol 12:10–19PubMedCrossRef Diaz LK, Sneige N (2005) Estrogen receptor analysis for breast cancer: current issues and keys to increasing testing accuracy. Adv Anat Pathol 12:10–19PubMedCrossRef
Metadata
Title
Acquisition of metastatic tissue from patients with bone metastases from breast cancer
Authors
J. F. Hilton
E. Amir
S. Hopkins
M. Nabavi
G. DiPrimio
A. Sheikh
S. J. Done
D. Gianfelice
F. Kanji
S. Dent
D. Barth
N. Bouganim
A. Al-Najjar
M. Clemons
Publication date
01-10-2011
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2011
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-010-1264-6

Other articles of this Issue 3/2011

Breast Cancer Research and Treatment 3/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine